Cancer Family
Mesothelial Neoplasm
CI-CAN-00000028Explore in graph →
Non-malignant108 active trials4 approved drugs13 evidence items
Loading cancer entity…
Cancer Family
CI-CAN-00000028Explore in graph →
Clinical trials
521 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06051695 | A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression(EVEREST-2) | recruiting | Phase 1 / Phase 2 | 474 | A2 Biotherapeutics Inc.INDUSTRY | 1 | Jun 12, 2026 | clinicaltrials |
| NCT06756035 | CT-95 in Advanced Cancers Associated With Mesothelin Expression | recruiting | Phase 1 | 70 | Context Therapeutics Inc.INDUSTRY | 1 | Jun 12, 2026 |
| clinicaltrials |
| NCT03918252 | Neoadjuvant Immune Checkpoint Blockade in Resectable Malignant Pleural Mesothelioma | active not recruiting | Phase 2 | 30 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jun 5, 2026 | clinicaltrials |
| NCT05765084 | Integration of the PD-L1 Inhibitor Atezolizumab and WT1/DC Vaccination Into Platinum/Pemetrexed-based First-line Treatment for Epithelioid Malignant Pleural Mesothelioma(Immuno-MESODEC) | recruiting | Phase 1 / Phase 2 | 15 | University Hospital, AntwerpOTHER | 1 | Jun 5, 2026 | clinicaltrials |
| NCT03935893 | Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers | active not recruiting | Phase 2 | 20 | Udai KammulaOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT06477419 | A Study of Sacituzumab Govitecan in People With Mesothelioma | recruiting | Phase 2 | 33 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 28, 2026 | clinicaltrials |
| NCT07602946 | SELECTmeso A Trial for Patients With Relapsed Malignant Mesothelioma SELECTmeso1 A Trial of BMS-986504 in Patients With MTAP-deficient Relapsed Mesothelioma(SELECTmeso) | not yet recruiting | Phase 2 | 30 | University of SouthamptonOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT06885424 | A Long-Term Follow-Up Study of Participants Treated With A2 Biotherapeutics (A2 Bio) Gene Therapy (GT) Products(DESCENT-1) | enrolling by invitation | — | 400 | A2 Biotherapeutics Inc.INDUSTRY | 1 | May 20, 2026 | clinicaltrials |
| NCT06503146 | 18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection | recruiting | Phase 2 | 320 | National Cancer Institute (NCI)NIH | 1 | May 19, 2026 | clinicaltrials |
| NCT03683680 | Prospectively Collected Pleural Biopsies for Validation of Malignant Pleural Mesothelioma Prognostic Biomarkers | recruiting | N/A | 240 | Dana-Farber Cancer InstituteOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT07563738 | A 2-part Phase 1/2 Open-label Trial on ODM-212(TEADCO) | recruiting | Phase 1 / Phase 2 | 229 | Orion Corporation, Orion PharmaINDUSTRY | 1 | May 4, 2026 | clinicaltrials |
| NCT07561190 | Multidimensional Omics Analysis in Malignant Pleural Mesothelioma(OMIM) | recruiting | — | 300 | Azienda USL Reggio Emilia - IRCCSOTHER_GOV | 1 | May 1, 2026 | clinicaltrials |
| NCT07550049 | Comprehensive Oncogenomic Mapping and Exploration in Thoracic and Head & Neck Oncology(COMETH) | not yet recruiting | — | 110 | University of Kansas Medical CenterOTHER | 0 | Apr 24, 2026 | clinicaltrials |
| NCT06638931 | Agnostic Therapy in Rare Solid Tumors(ANTARES) | recruiting | Phase 2 | 28 | Instituto do Cancer do Estado de São PauloOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT06362369 | A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy | recruiting | Phase 1 / Phase 2 | 126 | 7 Hills Pharma, LLCINDUSTRY | 1 | Apr 13, 2026 | clinicaltrials |
| NCT06444815 | A Study of VET3-TGI in Patients With Solid Tumors(STEALTH-001) | recruiting | Phase 1 | 60 | KaliVir ImmunotherapeuticsINDUSTRY | 1 | Apr 7, 2026 | clinicaltrials |
| NCT07443020 | Fast TILs to Treat Metastatic Pleural Effusions From Epithelial or Mesothelial Primary Tumors(RIOT 4B) | recruiting | Phase 1 | 10 | Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)OTHER | 1 | Apr 7, 2026 | clinicaltrials |
| NCT07514793 | Iparomlimab Plus Tovorilimab Combined With Bevacizumab and Chemotherapy as First-Line Treatment for Advanced Mesothelioma | not yet recruiting | Phase 2 | 37 | Fudan UniversityOTHER | 1 | Apr 7, 2026 | clinicaltrials |
| NCT07510815 | Dual-Target MSLN/FAP CAR-NK Cells for Pleural and Peritoneal Mesothelioma(DUAL-MESO-NK) | recruiting | Phase 1 / Phase 2 | 36 | Beijing BiotechINDUSTRY | 1 | Apr 6, 2026 | clinicaltrials |
| NCT04665206 | Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 434 | Vivace Therapeutics, IncINDUSTRY | 2 | Apr 2, 2026 | clinicaltrials |
| NCT03126630 | Pembrolizumab With or Without Anetumab Ravtansine in Treating Patients With Mesothelin-Positive Pleural Mesothelioma | active not recruiting | Phase 1 / Phase 2 | 49 | National Cancer Institute (NCI)NIH | 2 | Apr 1, 2026 | clinicaltrials |
| NCT05655078 | Hemithoracic Irradiation With Proton Therapy in Malignant Pleural Mesothelioma(HIT-Meso) | recruiting | N/A | 148 | University College, LondonOTHER | 1 | Mar 30, 2026 | clinicaltrials |
| NCT04450043 | The Transitions Project: Supporting Adults During the Shift From Cancer Treatment to Surveillance | active not recruiting | N/A | 21 | Massachusetts General HospitalOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT04897022 | A Study of Pembrolizumab and Radiation Therapy in People With Mesothelioma | active not recruiting | Phase 1 | 7 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Mar 12, 2026 | clinicaltrials |
| NCT04792463 | Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome | recruiting | — | 500 | Mohamed Abdel-RahmanOTHER | 1 | Mar 9, 2026 | clinicaltrials |
| NCT04028570 | A Feasibility Study Evaluating Surgery for Mesothelioma After Radiation Therapy Using Extensive Pleural Resection(SMARTER) | active not recruiting | N/A | 15 | University Health Network, TorontoOTHER | 1 | Mar 5, 2026 | clinicaltrials |
| NCT07420010 | An Open-label, Single-arm Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Profile, and Preliminary Efficacy of KT032 Cell Injection in Patients With Mesothelin-positive Advanced Solid Tumors. | not yet recruiting | Early Phase 1 | 24 | Weijia Fang, MDOTHER | 0 | Feb 19, 2026 | clinicaltrials |
| NCT07126509 | Partial Pleurectomy (Surgery) for Unresectable Pleural Mesothelioma | recruiting | N/A | 30 | University of ChicagoOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT07403630 | INTEGRATIVE "MULTI-OMICS" AND FUNCTIONAL PLATFORM FOR THE COMPLETE DIAGNOSTIC CHARACTERIZATION OF TUMORS: THE ITALIAN TUMOR CHEMOGENOMIC PROFILER (IT-TCP)(IT-TCP POS) | recruiting | N/A | 300 | Azienda Ospedaliero-Universitaria di ParmaOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT03269227 | Accelerated Hypofractionated Radiotherapy in the Treatment of Malignant Pleural Mesothelioma(MesoRT) | active not recruiting | N/A | 30 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCSOTHER | 1 | Jan 16, 2026 | clinicaltrials |
| NCT06155279 | Induction Chemo+Immunotherapy in Resectable Epithelioid and Biphasic Pleural Mesothelioma (CHIMERA Study)(CHIMERA) | active not recruiting | Phase 2 | 41 | Istituto Oncologico Veneto IRCCSOTHER | 1 | Jan 13, 2026 | clinicaltrials |
| NCT05544929 | A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers | active not recruiting | Phase 1 | 126 | Novartis PharmaceuticalsINDUSTRY | 12 | Jan 6, 2026 | clinicaltrials |
| NCT01385722 | Molecular Analysis of Thoracic Malignancies | enrolling by invitation | — | 1,000 | Stanford UniversityOTHER | 1 | Dec 26, 2025 | clinicaltrials |
| NCT07282873 | Study of TYK-01054 Capsules in Patients With Advanced Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 219 | TYK Medicines, IncINDUSTRY | 1 | Dec 22, 2025 | clinicaltrials |
| NCT03556228 | VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma | recruiting | Phase 1 / Phase 2 | 242 | VM Oncology, LLCINDUSTRY | 2 | Dec 11, 2025 | clinicaltrials |
| NCT03760575 | Pembrolizumab in Combination With Chemotherapy and Image-Guided Surgery for Malignant Pleural Mesothelioma (MPM) | recruiting | Phase 1 | 20 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Dec 4, 2025 | clinicaltrials |
| NCT03983954 | Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumor, Including a Cohort Expansion in Esophageal Cancer. | active not recruiting | Phase 1 | 120 | NeoTX Therapeutics Ltd.INDUSTRY | 2 | Nov 28, 2025 | clinicaltrials |
| NCT05238883 | A Study of HFB200301 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors | active not recruiting | Phase 1 | 72 | HiFiBiO TherapeuticsINDUSTRY | 2 | Nov 21, 2025 | clinicaltrials |
| NCT05730816 | MAGIC AKI: Magnesium for the Prevention of HIOC-Associated AKI(MAGIC-AKI) | recruiting | Phase 2 | 130 | Brigham and Women's HospitalOTHER | 1 | Nov 21, 2025 | clinicaltrials |
| NCT04115254 | Stereotactic Magnetic Resonance Guided Radiation Therapy | recruiting | N/A | 397 | Dana-Farber Cancer InstituteOTHER | 1 | Nov 13, 2025 | clinicaltrials |
| NCT06538376 | Clinical Utility of Portable Dynamic Chest X Ray (DDR) in the ICU | recruiting | N/A | 230 | Brigham and Women's HospitalOTHER | 1 | Oct 29, 2025 | clinicaltrials |
| NCT04400539 | The IMmunotherapy Pleural 5-ALA PDT(IMPALA) | recruiting | Phase 2 | 20 | University Hospital, LilleOTHER | 1 | Sep 25, 2025 | clinicaltrials |
| NCT05932199 | Neoadjuvant Durvalumab and Tremelimumab With and Without Chemotherapy for Mesothelioma | recruiting | Phase 1 / Phase 2 | 52 | Baylor College of MedicineOTHER | 1 | Sep 25, 2025 | clinicaltrials |
| NCT02628067 | Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158) | active not recruiting | Phase 2 | 1,609 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Sep 22, 2025 | clinicaltrials |
| NCT05107674 | A Study of NX-1607 in Adults With Advanced Malignancies | recruiting | Phase 1 | 345 | Nurix Therapeutics, Inc.INDUSTRY | 2 | Sep 9, 2025 | clinicaltrials |
| NCT03907852 | Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer | active not recruiting | Phase 1 / Phase 2 | 57 | TCR2 TherapeuticsINDUSTRY | 2 | Aug 27, 2025 | clinicaltrials |
| NCT05538806 | TTFields in General Routine Clinical Care in Patients With Pleural Mesothelioma Study(TIGER Meso) | recruiting | — | 198 | NovoCure Ltd.INDUSTRY | 3 | Aug 22, 2025 | clinicaltrials |
| NCT07131345 | Study of Iparomlimab and Tuvonralimab Plus Chemotherapy in Malignant Mesothelioma | not yet recruiting | Phase 1 / Phase 2 | 55 | National Cancer Center, ChinaOTHER | 0 | Aug 20, 2025 | clinicaltrials |
| NCT07121374 | NEoadjuvant Chemotherapy and Immunotherapy for a Selected Group of Inoperable Pleural Mesothelioma Patients (NECIM): a Feasibility Study(NECIM) | recruiting | Phase 1 / Phase 2 | 37 | University Hospital, AntwerpOTHER | 1 | Aug 13, 2025 | clinicaltrials |
| NCT07072143 | An International Study on Pediatric Patients With Rare Tumors.(PARTNER) | recruiting | — | 6,250 | Azienda Ospedaliera di PadovaOTHER | 1 | Jul 18, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Jun 12, 2026source: clinicaltrials